Bush would veto drug price bill

Share this article:
President Bush threatened on Thursday to veto legislation that would require the government to negotiate with pharmaceutical companies to obtain lower drug prices for Medicare beneficiaries, The New York Times reported. The House of Representatives was scheduled to consider a proposal on the issue Friday. “Government interference impedes competition, limits access to life-saving drugs, reduces convenience for beneficiaries and ultimately increases costs to taxpayers, beneficiaries and all American citizens alike,” the White House said in a written statement on the House bill. Chances for the passage of some version of the legislation may have increased when Senate Finance Committee chairman Max Baucus, Democrat of Montana, said that Congress should repeal the provision of the 2003 Medicare law that prohibits drug price negotiations, The Times reported. Baucus said he believed Medicare should be able to negotiate prices in “discrete areas where seniors need our help the most.” Baucus is reportedly seeking middle ground between Republicans, who strongly support the existing ban on federal price negotiations, and House Democratic leaders, who want to require the secretary of Health and Human Services to negotiate the prices that may be charged for most drugs covered by Medicare.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...